

**Deans, Assoc. Deans for Research, Center Directors, and Department Heads:
Please forward this information to the appropriate faculty immediately.**

Institutional Limit on Proposal Submissions

**National Institutes of Health
National Cancer Institute (NCI)**

Title: The Early Detection Research Network: Biomarker Reference Laboratories (U24)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-09-019.html>

RFA-CA-09-019

**NIH Letters of Intent (Not required) Deadline: September 29, 2009
Full NIH Proposal Deadline: October 29, 2009**

LIMITED SUBMISSION – ONE (1) PER INSTITUTION

Below is information about the National Institutes of Health Early Detection Research Network: Biomarker Reference Laboratories (U24) for 2009. NIH limits the number of proposals an organization can submit, as described above. Therefore, if the number of preproposals exceeds that limit (1), an internal review will be conducted to determine which proposals will be submitted from Mississippi State University.

If you are interested in submitting a proposal to the NIH, a preproposal that includes the information listed below must be submitted to the Office of Research and Economic Development (ORED), electronically to Teresa Gammill at tgammill@research.msstate.edu and **copied** to Katie Echols at kechols@research.msstate.edu in the ORED office by **5 p.m. on Friday, August 14, 2009**. A committee of faculty members will screen applications and select the nominee to represent the University.

All preproposals must include:

1. Title of NIH Grant
2. Proposal Deadline
3. Title of Proposal
4. PI and Co-PIs with title and unit affiliation
5. Partner institutions/industries (if any)
6. Indicate if this is a resubmission – If so include copies of panel summary and all reviews
7. One paragraph providing a brief description of the proposed activities.

Synopsis of Program:

This funding opportunity announcement (FOA) solicits cooperative agreement applications for Biomarker Reference Laboratories (BRLs), one of the four components of the Early Detection Research Network

(EDRN). EDRN is a national consortium funded to discover, develop, and validate biomarkers for early cancer detection, risk assessment and molecular diagnosis and prognosis of early cancer. The BRLs serve as a Network resource for clinical and laboratory validation of biomarkers, including technological developments and assay refinement. The other three main components of the EDRN are: the Biomarker Developmental Laboratories (BDLs), which have the responsibility for the development and characterization of new, or the refinement of existing, biomarkers and biomarker assays, the Clinical Validation Centers (CVCs), which conduct clinical research on the validation of biomarkers in early cancer detection and risk assessment and serve as resource centers for the EDRN by participating in collaborative biomarker validation studies and collaborating with EDRN BDLs and BRLs; and the Data Management and Coordinating Center (DMCC), which supports statistical and computational analyses, informatics infrastructure, and the coordination of network-wide meetings and conferences.

Budget and Project Period. An applicant may request a project period of up to 5 years at a budget of up to \$300,000 per year (direct costs).